approved

Приложение 4 от 02.11.2016

Unique identificator:  3e292905-ef8b-4985-bea5-aeb01d62af04

здравеопазване лекарства реимбурсиране

Current version: 1

Displayed version: 1

Format: CSV

  • Created at: 2016-11-09 09:28:59
  • Created by: georgi_sivchev
  • Updated at: 2018-10-16 08:08:28
  • Updated by: migrate_data
records per page
Order by:

ПОЗИТИВЕН ЛЕКАРСТВЕН СПИСЪК

Interferon beta-1b ЕU/1/08/454/002 Extavia, Powder and solvent for solution for injection, 9.6, MIU, Pack: 15 Novartis Europharm Limited, Обединено Кралство Novartis Pharma GmbH, Germany 981.81 196.36 1178.17 4% 10 991.81 198.36 1190.17 16% 25 1016.81 203.36 1220.17 НСР-7473/12.11.2015 27.11.2015 27.11.2015 Активен 3155
Interferon beta-1b ЕU/1/08/454/002 Extavia, Powder and solvent for solution for injection, 9.6, MIU, Pack: 15 Novartis Europharm Limited, Обединено Кралство Novartis Pharma GmbH, Germany 1027.26 205.45 1232.71 4% 10 1037.26 207.45 1244.71 16% 25 1062.26 212.45 1274.71 НСР-4537/22.08.2014 08.09.2014 08.09.2014 Неактивен 3155
Interferon beta-1b ЕU/1/08/454/002 Extavia, Powder and solvent for solution for injection, 9.6, MIU, Pack: 15 Novartis Europharm Limited, Обединено Кралство Novartis Pharma GmbH, Germany 1257.27 251.45 1508.72 4% 10 1267.27 253.45 1520.72 16% 25 1292.27 258.45 1550.72 промяна на обстоятелства НСР-4521/22.08.2014 ( в сила от 08.09.2014) НСР-1733/21.11.2013 09.12.2013 09.12.2013 Неактивен 3155
Interferon beta-1b ЕU/1/08/454/002 Extavia, Powder and solvent for solution for injection, 9.6, MIU, Pack: 15 Novartis Europharm Limited, Обединено Кралство Novartis Pharmaceuticals UK Limited, Обединеното кралство 1259.53 251.91 1511.44 4% 10 1269.53 253.91 1523.44 16% 25 1294.53 258.91 1553.44 КЦРР-2188/06.02.2013 г 25.02.2013 25.02.2013 Неактивен 3155
Interferon beta-1b ЕU/1/08/454/002 Extavia, Powder and solvent for solution for injection, 9.6, MIU, Pack: 15 Novartis Europharm Limited, Обединено Кралство Novartis Pharmaceuticals UK Limited, Обединеното кралство 1737.21 347.44 2084.65 4% 10 1747.21 349.44 2096.65 16% 25 1772.21 354.44 2126.65 КЦ-259/20.10.2008 08.11.2008 08.11.2008 Неактивен 3155
Isotonic Solutions II-9718/31.05.2010 EXTRANEAL, Solution for peritoneal dialysis, Icodextrin 75 g/l; Sodium chloride 5.4 g/l; Calcium chloride 0.257 g/l, Magnesium chloride 0.051 g/l; Sodium lactate solution 4.5 g/l - 2000 ml, g, Pack: 1 Бакстер България ЕООД, България Baxter Healthcare S.A. Moneen Road, Castlebar, County Mayo, Ирландия; Baxter Healthcare Ltd., Caxton Way, Thetford, Norfolk IP24 3SE, UK 13.46 2.69 16.15 6% 0.81 14.27 2.85 17.12 18% 2.42 16.69 3.34 20.03 промяна в обстоятелства НСР-5173/27.11.2014 КЦ-1706/09.09.2010 24.09.2010 24.09.2010 Активен 957
Dasabuvir EU/1/14/983/001 Exviera, Film coated tablet, 250, mg, Pack: 56 AbbVie Ltd, Обединено Кралство AbbVie Deutschland GmbH & Co. KG, Knollstrasse 67061 Ludwigshafen, Германия 2039.23 407.85 2447.08 4% 10 2049.23 409.85 2459.08 16% 25 2074.23 414.85 2489.08 НСР-7450/10.11.2015. (допуска се предварително изпълнение); НСР-9629/23.06.2016 02.08.2016 02.08.2016 Активен 4092
Dasabuvir EU/1/14/983/001 Exviera, Film coated tablet, 250, mg, Pack: 56 AbbVie Ltd, Обединено Кралство AbbVie Deutschland GmbH & Co. KG, Knollstrasse 67061 Ludwigshafen, Германия 2188.12 437.62 2625.74 4% 10 2198.12 439.62 2637.74 16% 25 2223.12 444.62 2667.74 НСР-7450/10.11.2015. (допуска се предварително изпълнение) 10.11.2015 10.11.2015 Неактивен 4092
Aflibercept EU/1/12/797/002 Eylea, Solution for injection, 40 mg/ml - 100µl, mg, Pack: 1 vial Bayer Pharma AG, Германия Bayer Pharma AG, Müllerstraße 178, D-13353 Berlin, Германия 1250.75 250.15 1500.9 4% 10 1260.75 252.15 1512.9 16% 25 1285.75 257.15 1542.9 промяна на обстоятелства НСР-9687/30.06.2016 НСР-7570/26.11.2015. 12.12.2015 12.12.2015 Активен 4126
Aflibercept EU/1/12/797/002 Eylea, Solution for injection, 40 mg/ml - 100µl, mg, Pack: 1 vial Bayer Pharma AG, Германия Bayer Pharma AG, Müllerstraße 178, D-13353 Berlin, Германия; GP Grenzach Produktions GmbH, Emil -Barell-Straße 7, D-79639 Grenzach-Wyhlen, Германия 1250.75 250.15 1500.9 4% 10 1260.75 252.15 1512.9 16% 25 1285.75 257.15 1542.9 НСР-7570/26.11.2015. 12.12.2015 12.12.2015 Неактивен 4126
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., 37 Hollands Road, Haverhill Suffolk CB9 8PU, Великобритания; Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия 5170.94 1034.19 6205.13 4% 10 5180.94 1036.19 6217.13 16% 25 5205.94 1041.19 6247.13 промяна в обстоятелства НСР-8697/06.04.2016; корекционно решение НСР-9730/07.07.2016 НСР-4745/02.10.2014; НСР-9480/09.06.2016 02.07.2016 02.07.2016 Активен 3215
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., 37 Hollands Road, Haverhill Suffolk CB9 8PU, Великобритания; Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия 5170.94 1034.19 6205.13 4% 10 5180.94 1036.19 6217.13 16% 25 5205.94 1041.19 6247.13 промяна в обстоятелства НСР-8697/06.04.2016. НСР-4745/02.10.2014; НСР-9480/09.06.2016 02.07.2016 02.07.2016 Неактивен 3215
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., 37 Hollands Road, Haverhill Suffolk CB9 8PU, Великобритания; Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия 5205.48 1041.1 6246.58 4% 10 5215.48 1043.1 6258.58 16% 25 5240.48 1048.1 6288.58 промяна в обстоятелства НСР-8697/06.04.2016. НСР-4745/02.10.2014 16.10.2014 16.10.2014 Неактивен 3215
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., United Kingdom 5432.26 1086.45 6518.71 4% 10 5442.26 1088.45 6530.71 16% 25 5467.26 1093.45 6560.71 НСР-2288/13.01.2014 21.02.2014 21.02.2014 Неактивен 3215
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., United Kingdom 5811.92 1162.38 6974.3 4% 10 5821.92 1164.38 6986.3 16% 25 5846.92 1169.38 7016.3 КЦРР-2773/20.03.2013 19.04.2013 19.04.2013 Неактивен 3215
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., United Kingdom 5861.64 1172.33 7033.97 4% 10 5871.64 1174.33 7045.97 16% 25 5896.64 1179.33 7075.97 КЦРР-756/07.06.2012 31.07.2012 31.07.2012 Неактивен 3215
Agalsidase beta EU/1/01/188/001 Fabrazyme, Powder for concentrate for solution for infusion, 35, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., United Kingdom 6354.61 1270.92 7625.53 6% 15 6369.61 1273.92 7643.53 18% 30 6399.61 1279.92 7679.53 КЦ-599/23.02.2009 12.03.2009 12.03.2009 Неактивен 3215
Famotidine 15637/29.12.2006 г. FAMOTIDINE ALKALOID, Film coated tablet, 20, mg, Pack: 20 Алкалоид ЕООД, България Alkaloid-INT d.o.o. Slovenia 0.82 0.16 0.98 7% 0.06 0.88 0.18 1.06 20% 0.16 1.04 0.21 1.25 промяна на обстоятелства решение КЦPP-2321/20.02.2013; цената е заличена с решение НСР-4837/17.10.2014 (в сила от 16.11.2014 ) КЦ-221/19.09.2008 21.10.2008 21.10.2008 Заличен 113
Famotidine 16196/06.04.2007 Famultran, Film coated tablet, 40, mg, Pack: 30 Актавис EАД, България Балканфарма- Дупница АД 2.8 0.56 3.36 7% 0.2 3 0.6 3.6 20% 0.56 3.56 0.71 4.27 КЦ-222/19.09.2008 21.10.2008 21.10.2008 Активен 89
Famotidine 16195/06.04.2007 Famultran, Film coated tablet, 20, mg, Pack: 30 Актавис EАД, България Балканфарма- Дупница АД 1.5 0.3 1.8 7% 0.11 1.61 0.32 1.93 20% 0.3 1.91 0.38 2.29 КЦ-222/19.09.2008 21.10.2008 21.10.2008 Активен 88
Human coagulation factor VIII II-6211/18,11,2009 Fanhdi, Powder and solvent for solution for injection, 1000, IU, Pack: 1 Instituto Grifols, S.A., Испания INSTITUTO GRIFOLS S.A.,Spain 648.87 129.77 778.64 4% 10 658.87 131.77 790.64 16% 25 683.87 136.77 820.64 КЦ-1449/09.03.2010; протокол №16/04.07.2013. 26.03.2010 26.03.2010 Активен 904
Human coagulation factor VIII II-6211/18,11,2009 Fanhdi, Powder and solvent for solution for injection, 1000, IU, Pack: 1 Instituto Grifols, S.A., Испания INSTITUTO GRIFOLS S.A.,Spain 648.87 129.77 778.64 4% 10 658.87 131.77 790.64 16% 25 683.87 136.77 820.64 КЦ-1449/09.03.2010; протокол №16/04.07.2013. 26.03.2010 26.03.2010 Неактивен 904
Human coagulation factor VIII II-6209/18,11,2009 Fanhdi, Powder and solvent for solution for injection, 500, IU, Pack: 1 Instituto Grifols, S.A., Испания INSTITUTO GRIFOLS S.A.,Spain 324.43 64.89 389.32 4% 10 334.43 66.89 401.32 16% 25 359.43 71.89 431.32 КЦ-1449/09.03.2010; протокол №16/04.07.2013. 26.03.2010 26.03.2010 Активен 903
Human coagulation factor VIII II-6209/18,11,2009 Fanhdi, Powder and solvent for solution for injection, 500, IU, Pack: 1 Instituto Grifols, S.A., Испания INSTITUTO GRIFOLS S.A.,Spain 324.43 64.89 389.32 4% 10 334.43 66.89 401.32 16% 25 359.43 71.89 431.32 КЦ-1449/09.03.2010; протокол №16/04.07.2013. 26.03.2010 26.03.2010 Неактивен 903
Human coagulation factor VIII II-6210/18,11,2009 Fanhdi, Powder and solvent for solution for injection, 250, IU, Pack: 1 Instituto Grifols, S.A., Испания INSTITUTO GRIFOLS S.A.,Spain 161.16 32.23 193.39 4% 6.45 167.61 33.52 201.13 16% 25 192.61 38.52 231.13 КЦ-1449/09.03.2010; протокол №16/04.07.2013. 26.03.2010 26.03.2010 Активен 902
Showing 3001 to 3026 of 9938 entries
Download link in CSV format: Copy
Download link in JSON format: Copy
Download link in XML format: Copy
 

Моля изчакайте